BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20507928)

  • 1. Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.
    Coopman K; Huang Y; Johnston N; Bradley SJ; Wilkinson GF; Willars GB
    J Pharmacol Exp Ther; 2010 Sep; 334(3):795-808. PubMed ID: 20507928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
    Li N; Lu J; Willars GB
    PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
    Cheong YH; Kim MK; Son MH; Kaang BK
    Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.
    Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
    J Pharmacol Exp Ther; 2015 Apr; 353(1):52-63. PubMed ID: 25630467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.
    Koole C; Wootten D; Simms J; Savage EE; Miller LJ; Christopoulos A; Sexton PM
    J Biol Chem; 2012 Feb; 287(6):3659-73. PubMed ID: 22147709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
    Nakane A; Gotoh Y; Ichihara J; Nagata H
    Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.
    Koole C; Wootten D; Simms J; Valant C; Sridhar R; Woodman OL; Miller LJ; Summers RJ; Christopoulos A; Sexton PM
    Mol Pharmacol; 2010 Sep; 78(3):456-65. PubMed ID: 20547734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
    Irwin N; Flatt PR; Patterson S; Green BD
    Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
    Heller RS; Kieffer TJ; Habener JF
    Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
    Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.
    Koole C; Wootten D; Simms J; Valant C; Miller LJ; Christopoulos A; Sexton PM
    Mol Pharmacol; 2011 Sep; 80(3):486-97. PubMed ID: 21616920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
    Thompson A; Stephens JW; Bain SC; Kanamarlapudi V
    PLoS One; 2016; 11(4):e0154229. PubMed ID: 27100083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmembrane α-helix 2 and 7 are important for small molecule-mediated activation of the GLP-1 receptor.
    Rye Underwood C; Møller Knudsen S; Schjellerup Wulff B; Bräuner-Osborne H; Lau J; Knudsen LB; Peters GH; Reedtz-Runge S
    Pharmacology; 2011; 88(5-6):340-8. PubMed ID: 22134089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
    Morris LC; Days EL; Turney M; Mi D; Lindsley CW; Weaver CD; Niswender KD
    J Biomol Screen; 2014 Jul; 19(6):847-58. PubMed ID: 24525870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.
    Wootten D; Simms J; Koole C; Woodman OL; Summers RJ; Christopoulos A; Sexton PM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):540-50. PubMed ID: 21075839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-converting enzyme-1 regulates glucagon-like peptide-1 receptor signalling and resensitisation.
    Lu J; Willars GB
    Biochem J; 2019 Feb; 476(3):513-533. PubMed ID: 30626614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
    Zhang H; Liu Y; Guan S; Qu D; Wang L; Wang X; Li X; Zhou S; Zhou Y; Wang N; Meng J; Ma X
    PLoS One; 2016; 11(2):e0148827. PubMed ID: 26863436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery.
    Harikumar KG; Wootten D; Pinon DI; Koole C; Ball AM; Furness SG; Graham B; Dong M; Christopoulos A; Miller LJ; Sexton PM
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):18607-12. PubMed ID: 23091034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s).
    Jorgensen R; Kubale V; Vrecl M; Schwartz TW; Elling CE
    J Pharmacol Exp Ther; 2007 Jul; 322(1):148-54. PubMed ID: 17395766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.